<DOC>
	<DOCNO>NCT02605694</DOCNO>
	<brief_summary>Phase II study evaluate efficacy safety DR vs R-CHOP subject relapsed/refractory FL</brief_summary>
	<brief_title>Duvelisib With Rituximab v R-CHOP Subjects With Relapsed/Refractory Follicular Lymphoma ( FRESCO )</brief_title>
	<detailed_description>This phase 2 , randomize , two-arm , open-label study design evaluate efficacy safety Duvelisib Administered Combination Rituximab v R-CHOP Subjects Relapsed/Refractory Follicular Lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Diagnosis FL : Grade 1 , 2 , 3a 2 . Progressed within 24 month initiate alkylatorbased chemotherapy regimen give either first secondline therapy ; singleagent chlorambucil therapy fulfill requirement Note : subject must receive least 2 cycle alkylatorbased chemotherapy eligible 3 . Previously receive rituximab , either single agent part combination regimen , also meet one follow requirement : 1 . Progressed within 24 month initiate alkylatorbased chemotherapy first line receive additional anticancer therapy 2 . Progressed within 24 month initiate alkylatorbased chemotherapy first line subsequently progress within 24 month receive secondline treatment receive additional anticancer therapy 3 . Progressed within 24 month initiate alkylatorbased chemotherapy second line receive additional anticancer therapy 4 . Appropriate receive RCHOP 5 . At least 1 measurable disease lesion &gt; 1.5 cm least one dimension compute tomography ( CT ) , CTPET , magnetic resonance imaging ( MRI ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ( correspond Karnofsky Performance Status [ ( KPS ) ≥60 % ] ) 7 . For woman childbearing potential ( WCBP ) : negative serum β human chorionic gonadotropin ( βhCG ) pregnancy test within 1 week first treatment ( WCBP define sexually mature woman undergone surgical sterilization naturally postmenopausal least 12 consecutive month woman &gt; 55 year age ) 1 . Clinical evidence transformation aggressive subtype lymphoma grade 3B FL 2 . Received ≥ 3 previous anticancer regimens prior enrollment 3 . Received prior RCHOP therapy 4 . Previous receipt anthracycline 5 . Contraindication individual component CHOP ( cyclophosphamide , vincristine , doxorubicin prednisone ) Severe allergic anaphylactic reaction monoclonal antibody therapy , murine protein , know hypersensitivity study drug 6 . Received prior allogeneic transplant 7 . Received prior treatment phosphoinositide3kinase ( PI3K ) inhibitor 8 . History tuberculosis treatment within two year prior randomization 9 . History chronic liver disease , venoocclusive disease , alcohol abuse 10 . Ongoing treatment chronic immunosuppressant ( e.g. , cyclosporine ) systemic steroid &gt; 20 mg prednisone ( equivalent ) QD 11 . Ongoing treatment systemic bacterial , fungal , viral infection screen 12 . Concurrent administration medication food strong inhibitor inducer cytochrome P450 3A ( CYP3A ) 13 . Unable receive prophylactic treatment pneumocystis , herpes simplex virus ( HSV ) , herpes zoster ( VZV ) screen 14 . Concurrent active malignancy nonmelanoma skin cancer , carcinoma situ cervix 15 . History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication pacemaker within last 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>